Open an account

Gain Therapeutics

GANX · NASDAQ

$1.19−$0.06 (−4.80%)TodayMarket closed ·
Prev close $1.25

About GANX

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. The company is headquartered in Bethesda, Maryland and currently employs 20 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Employees
20
Headquarters
Bethesda, Maryland
Listed
Mar 18, 2021
Sector
Health Care
Industry
Biotechnology
Website
gaintherapeutics.com

GANX key statistics

Market cap
51.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
529.67K
Volume
517.01K
Open price
$1.23
High today
$1.30
Low today
$1.17
52 Week high
$4.34
52 Week low
$1.21

Gain Therapeutics (GANX) at a glance

As of Oct 20, 2026, Gain Therapeutics (GANX) shares are priced at $1.19, giving the company a market cap of 51.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.17 and $1.30. The current price is 1.7% above the day's low and 8.1% below its high.

Volume so far is 517.01K shares, in line with the average of 529.67K shares a day.

Over the past year Gain Therapeutics has ranged from $1.21 to $4.34, and now sits -1% of the way up that range.

Gain Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1448.

The average analyst price target is $7.34, 517.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $7.34
Low
$5.05
Now
$1.19
High
$8.40

GANX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 19.4% on average.

  1. Q3 FY24: reported -$0.17 per share against an estimate of -$0.2193
  2. Q4 FY24: reported -$0.11 per share against an estimate of -$0.187
  3. Q1 FY25: reported -$0.16 per share against an estimate of -$0.1836
  4. Q2 FY25: reported -$0.19 per share against an estimate of -$0.1717
  5. Q3 FY25: reported -$0.15 per share against an estimate of -$0.153
  6. Q4 FY25: reported -$0.11 per share against an estimate of -$0.1479
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.1403
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1448

GANX news

  • Press releaseGlobe Newswire

    Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseGlobe Newswire

    Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

  • Press releaseGlobe Newswire

    Gain Therapeutics to Present at the 38th Annual ROTH Conference

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Press releaseGlobe Newswire

    Gain Therapeutics to Attend the 2025 Maxim Growth Summit

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Rishabh Mishra

    US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus

Similar companies

Companies in the same industry as Gain Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.